Agios Reports Business Highlights and First Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Agios Pharma (AGIO) Tops Q1 EPS by 7c
May 5, 2022 7:13 AM EDTAgios Pharma (NASDAQ: AGIO) reported Q1 EPS of ($1.74), $0.07 better than the analyst estimate of ($1.81). Revenue for the quarter came in at $800 thousand versus the consensus estimate of $2.75 million.
For earnings history and earnings-related data on Agios Pharma (AGIO) click here.
... More